Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC) and Lyra Therapeutics (LYRA).
Teladoc (TDOC)
Jefferies analyst David Windley maintained a Hold rating on Teladoc on August 5 and set a price target of $205.00. The company’s shares closed last Friday at $193.72.
According to TipRanks.com, Windley is a top 100 analyst with an average return of 19.7% and a 73.8% success rate. Windley covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Molina Healthcare, and IQVIA Holdings.
Teladoc has an analyst consensus of Moderate Buy, with a price target consensus of $235.20, implying a 9.4% upside from current levels. In a report issued on July 30, Barclays also maintained a Hold rating on the stock with a $230.00 price target.
See today’s analyst top recommended stocks >>
Lyra Therapeutics (LYRA)
In a report issued on August 5, Chris Howerton from Jefferies reiterated a Buy rating on Lyra Therapeutics, with a price target of $24.00. The company’s shares closed last Friday at $13.50.
According to TipRanks.com, Howerton is ranked 0 out of 5 stars with an average return of -7.4% and a 35.4% success rate. Howerton covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Milestone Pharmaceuticals, and Protagonist Therapeutics.
Lyra Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
